Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Home
Profiles
Research units
Research output
Prizes
Search by expertise, name or affiliation
Innovative drugs for allergies
Ekaterini Tiligada
*
, Kyriaki Gerasimidou
,
Francesca Levi-Schaffer
*
Corresponding author for this work
School of Pharmacy
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
peer-review
1
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Innovative drugs for allergies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Activated B Cells
20%
Allergen
20%
Allergic Diseases
100%
Allergic Inflammation
20%
Allergy
100%
Anti-interleukin 5
20%
Antihistamines
20%
Armamentarium
20%
Asthma
20%
Atopic Dermatitis
20%
Basophils
20%
Bioengineering
20%
Cellular Mechanisms
20%
Chronic Spontaneous Urticaria
20%
Class Switch Recombination
20%
Clinical Efficacy
20%
Clinical Evaluation
20%
Corticosteroids
20%
Cytokine Receptor
20%
Drug Candidates
20%
Dupilumab
40%
Environmental Antigens
20%
Eosinophils
20%
Functional Activation
20%
Histamine H1 Receptor
20%
Human Use
20%
Humanized Mab
20%
Immune Response
20%
Immunoglobulin E
40%
Immunopharmacology
20%
Inflammatory Response
20%
Inhaled Corticosteroids
20%
Innovative Drugs
100%
Interleukin-13 (IL-13)
40%
Interleukin-4 (IL-4)
40%
Interleukin-4 Receptor
20%
Interleukin-4R
20%
Interleukin-5 (IL-5)
20%
Maintenance Therapy
20%
Market Authorization
20%
Mast Cells
20%
Mepolizumab
20%
Moderate to Severe
20%
Moderate-to-severe Atopic Dermatitis
20%
Molecular Mechanism
20%
Monoclonal Antibody
60%
Omalizumab
20%
Personalized Medicine
20%
Plethora
20%
Preclinical Evaluation
20%
Reslizumab
20%
Severe Eosinophilic Asthma
20%
Severe Persistent Asthma
20%
Small Molecule Drugs
20%
Successful Development
20%
Symptomatic Medication
20%
T Helper 2
20%
Th2 Cytokines
20%
Therapeutic Approaches
20%
Therapeutic Intervention
20%
Translational Research
20%
Immunology and Microbiology
Allergen
33%
Allergic Inflammation
33%
Asthma
33%
Atopic Dermatitis
66%
B Cell
33%
Basophil Granulocyte
33%
Biological Product
66%
Chronic Urticaria
33%
Cytokine
100%
Cytokine Receptor
33%
Dupilumab
66%
Eosinophil
33%
Histamine
33%
Human Monoclonal Antibody
33%
Immune Response
33%
Immunoglobulin Antibody
33%
Immunoglobulin Class Switching
33%
Immunoglobulin E
66%
Immunopharmacology
33%
Inflammation Response
33%
Interleukin 13
66%
Interleukin 4
66%
Interleukin 5
66%
Interleukin-4 Receptor
33%
Mast Cell
33%
Mepolizumab
33%
Monoclonal Antibody
66%
Omalizumab
33%
Reslizumab
33%
Severe Persistent Asthma
33%
T Helper 2 Cell
33%
Pharmacology, Toxicology and Pharmaceutical Science
Allergen
33%
Antihistaminic Agent
33%
Asthma
66%
Atopic Dermatitis
66%
Biological Product
66%
Chronic Urticaria
33%
Clinical Trial
33%
Cytokine
100%
Cytokine Receptor
33%
Diseases
66%
Dupilumab
66%
Histamine H1 Receptor
33%
Human Monoclonal Antibody
33%
Immune System Pharmacology
33%
Immunoglobulin Antibody
33%
Immunoglobulin E
66%
Inflammation
66%
Interleukin 13
66%
Interleukin 4
66%
Interleukin 4 Receptor
33%
Interleukin 5
66%
Mepolizumab
33%
Monoclonal Antibody
66%
Omalizumab
33%
Reslizumab
33%
Severe Persistent Asthma
33%
Medicine and Dentistry
Immunoglobulin Class Switching
33%